NBTXR3 with chemoradiation for esophageal cancer treatment
Part of Cancer, Digestive system clinical trials.
This early-phase study tests adding NBTXR3 (a special treatment given into the tumor) to standard chemotherapy and radiation for esophageal cancer. The goal is to see if it can improve cancer control and to learn about safety and dosing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer is confirmed by biopsy as adenocarcinoma of the esophagus (neck or chest area) or the gastroesophageal junction
- Your cancer is stage II or III (spread outside the area of the esophagus on scans usually excludes you)
- You must be able to get standard chemoradiation using one of several approved chemotherapy combinations (the team will match you to a regimen)
- You must be eligible for an ultrasound-guided injection into the esophagus tumor (endoscopic ultrasound, called EUS)
- Scans must show 1 to 4 measurable tumor spots in the esophagus that the study can track over time
- Your blood counts and organ function (kidneys, liver) must meet minimum limits, and you must be able to participate with an ECOG status of 0–2
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter course of radiation combined with chemotherapy (FOLFOX) before surgery for esophageal or stomach-junction cancer. It aims to reduce side effects and still improve outcomes.
This trial compares two chemotherapy combinations, with or without an immunotherapy drug called nivolumab, for people with advanced stomach, esophagus, or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see which treatment works better and if adding immunotherapy helps.
This trial tests a combination of three drugs for advanced stomach or esophagus cancer that hasn't been treated much. The goal is to see if this combination helps shrink or control the cancer.
This trial tests adding medicines that block TGF-beta and PD-L1 to standard chemoradiation for esophageal squamous cell cancer that can’t be removed with surgery. It aims to improve control of the cancer where it sits, while keeping treatment safe.
This trial tests a new approach before surgery: a short course of radiation (5 treatments) combined with chemotherapy and immunotherapy. The goal is to shrink the tumor and increase the chance of successful removal, while hopefully reducing side effects and improving long-term outcomes.
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
Hear when a new Clinical Stage II Esophageal Adenocarcinoma AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.